Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial (vol 394, pg 1940, 2019)H. G. M. Heijerman,E. F. McKone,D. G. Downey,Eva Van Braeckel,Steven M. Rowe,Elizabeth Tullis,Marcus A. Mall,John J. Welter,Bonnie W. Ramsey,Charlotte M. McKee,Gautham Marigowda,Samuel M. Moskowitz,David Waltz,Patrick R. Sosnay,Christopher Simard,Neil Ahluwalia,Fengjuan Xuan,Yaohua Zhang,Jennifer L. Taylor-Cousar,Karen S. McCoyLANCET(2020)引用 719|浏览22暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要